IP Library › Granted Patent US 11,160,833
Granted Patent B2
US 11,160,833 · App. 17/028,701 · Granted Nov 2, 2021

Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20

Inventors: Yvonne Y. Chen (Los Angeles, CA); Eugenia Zah (Los Angeles, CA); Michael C. Jensen (Seattle, WA)
Assignees: The Regents of the University of California; Seattle Children's Hospital
A61K35/17C07K14/7051C07K14/70521C07K14/70596C07K16/2803C07K16/2887C07K16/46C12N5/0636A61K38/00A61K2039/505C07K2317/31C07K2317/622C07K2319/03C07K2319/40C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,160,833
App. No.
17/028,701
Filed
Sep 22, 2020
Granted
Nov 2, 2021
Kind
B2
Art Unit
1644
USPC
424/139.1
Abstract

A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

Claims (10)

1. A polypeptide comprising a CD19-OR-CD20 chimeric antigen receptor (CAR), comprising in order: anti CD20 scFv comprising a light chain variable region and heavy chain variable region from SEQ ID NO:3; (G4S)4 linker; anti-CD19 scFv comprising a heavy chain variable region and light chain variable region from SEQ ID NO:4; spacer domain of SEQ ID NO:5; transmembrane domain of SEQ ID NO:6; 4-1 BB cytoplasmic signaling domain of SEQ ID NO:8; CD3 zeta signaling domain of SEQ ID NO:9.

2. The polypeptide of claim 1 , wherein the polypeptide further comprises a sortable tag.

3. A nucleic acid encoding a polypeptide according to claim 1 .

4. A cell comprising the polypeptide of claim 1 .

5. The cell of claim 4 , wherein the cell is a T cell.

6. The polypeptide of claim 2 , wherein the polypeptide further comprises a T2A cleavage site between the CAR and sortable tag.

7. The polypeptide of claim 6 , wherein the T2A cleavage site comprises SEQ ID NO:10.

8. The polypeptide of claim 1 , wherein the CAR consists of, in order: anti CD20 scFv having the light chain variable region and heavy chain variable region from SEQ ID NO:3; (G4S)4linker; anti-CD19 scFv having the heavy chain variable region and light chain variable region from SEQ ID NO:4; the spacer domain of SEQ ID NO:5; the transmembrane domain of SEQ ID NO:6; the 4-1 BB cytoplasmic signaling domain of SEQ ID NO:8; and the CD3 zeta signaling domain of SEQ ID NO:9.

9. The polypeptide of claim 1 , wherein the polypeptide further comprises a signal sequence of SEQ ID NO:2.

10. A cell comprising the nucleic acid of claim 3 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2021
From: JENSEN, MICHAEL C.
To: SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
Reel/Frame 057438/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2020
From: CHEN, YVONNE Y.; ZAH, EUGENIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 054553/0323 →
Continuity (3)
Division 15535972
Provisional Application 62091854 · Dec 15, 2014
Related Publication 20210145880A1 · May 20, 2021
Cited By (2)
US 12,226,435 US 12,233,090